Login to Your Account



Genentech, XOMA Come Through With Strong Phase III Raptiva Data

By Brady Huggett


Wednesday, September 18, 2002
When trying to get a drug approved, biotechnology companies must provide the FDA with data - data showing that a drug is efficacious, that it works in the appropriate patient and that it is safe, among other things. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription